Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer
Roche announced results from the Phase III persevERA Breast Cancer study evaluating the investigational oral selective estrogen receptor degrader (SERD) giredestrant in combination with the CDK4/6 inhibitor palbociclib for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer.
The study assessed whether the combination therapy could improve outcomes compared with standard endocrine therapy combined with a CDK4/6 inhibitor in patients whose disease had progressed following prior treatment. Results demonstrated that the giredestrant-...